Distinguishing the Mechanisms of Tumoral Immune Response and Cutaneous Adverse Events

Checkpoint inhibitor (CPI) therapy has revolutionized cancer treatment, but generates immune-related adverse events (irAEs) that commonly include cutaneous effects. I hypothesize that the tumor response is mechanistically distinct from associated…

Read More
Joel Sunshine M.D.

Loss of Effective Antigen Presentation in Melanoma and Treatment Failure

Loss of effective presentation of tumor antigens by melanoma may drive immunotherapy resistance. We will use multiplex immunofluorescence to map antigen presentation at single-cell resolution across whole slides, and correlate…

Read More
Steven Chen M.D.

Investigation of Dermatologic Toxicity from Immune Checkpoint Blockade in Advanced Malignancies

Advanced malignancies are increasingly being treated with immune checkpoint inhibitors, which can lead to immune-related adverse events (irAEs), including those in the skin. This project will investigate key clinical, pathologic,…

Read More

Identifying Molecular Determinants of Prognosis in Advanced Squamous Cell Carcinoma

Immunotherapy is a crucial treatment for advanced squamous cell cancers that cannot be cured by surgery alone. But it works only half of the time, and we do not know…

Read More